Can-Fite BioPharma (CANF) said Monday that the first patient has been dosed in its phase 2a trial of Namodenoson in patients with advanced pancreatic adenocarcinoma.
The company said it targets to enroll about 20 evaluable patients in the trial.
The study's primary objective is to characterize Namodenoson's safety profile, while the secondary objective is to evaluate clinical activity using overall response rate, overall survival, and progression-free survival, among others, Can-Fite added.
Price: 2.7500, Change: -0.07, Percent Change: -2.48
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。